直接口服抗凝藥（包括阿哌沙班、達(dá)比加群、依度沙班和利伐沙班）與傳統(tǒng)抗凝藥物相比，出血風(fēng)險(xiǎn)更低，且不需要監(jiān)測凝血功能。目前關(guān)于這兩類藥物之間發(fā)生相互作用及其機(jī)制的研究較少，但其都可以通過細(xì)胞色素P450酶系和P-糖蛋白對其他藥物產(chǎn)生影響，潛在的相互作用可能會(huì)增加與直接口服抗凝藥相關(guān)出血的風(fēng)險(xiǎn)或降低其抗血栓作用，同時(shí)也能增加癲癇發(fā)作的風(fēng)險(xiǎn)。對抗癲癇藥物與直接口服抗凝藥藥動(dòng)學(xué)相互作用的研究進(jìn)展進(jìn)行綜述，以期為安全用藥提供依據(jù)。

Direct oral anticoagulants, namely apixaban, dabigatran, edoxaban, and rivaroxaban, which are considered to be associated to lower bleeding risk than classical anticoagulants, and do not require coagulation monitoring. At present, there was few studies on the interaction and mechanism between the two drugs, but both drugs can affect other drugs through cytochrome P450 enzyme system and P-glycoprotein. The progress of pharmacokinetic interaction between antiepileptic drugs and direct oral anticoagulants iwas reviewed, in order to provide a basis for the safe use of these drugs.

R969.2